Drugs / PXS-5505
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05109052 | Sep 2022 → Dec 2028 | hepatocellular carcinoma | University of Rochester | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT04676529 | Feb 2021 → Jul 2025 | myelofibrosis | Syntara | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PXS-5505 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04676529 ↗ |
| Action | Inhibit | “PXS-5505 is a novel pan-lysyl oxidase inhibitor” PMID 40241543 ↗ Apr 2025 |